Live Chat ×
Skip to main content

Bi-Specific Monoclonal Antibodies: A New Paradigm in Development

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Mark Chiu, Janssen R&D

    Dr. Mark Chiu is an Associate Director in the Department of Structural Biology of Janssen BioTherapeutics which is part of Johnson and Johnson at Spring House, Pennsylvania. Mark received a B.A. Biophysics from University of California, Berkeley and a Ph.D. Biochemistry from the University of Illinois Urbana-Champaign. He was a post-doctoral fellow at the ETH-Zurich and at the Biocenter at the University of Basel. Mark has worked as a synthetic organic chemist in Microgenics, an Assistant Professor of Chemistry at Seton Hall University, and a Research Investigator in the Department of Structural Biology at Abbott Laboratories. Currently, Mark is leading the Biologics, Engineering, and Function group that uses protein engineering to generate fit for purpose biologics candidates. Outside of work, Mark explores the symbiosis of invertebrates and native flora.

November 10, 2016
Thu 12:30 PM EST

Duration 1H 30M

This live web event has ended.